Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 3Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Cytokine Release Syndrome 2Schwannomatosis 1Pain 1Neurilemmoma 1Neoplasms, Plasma Cell 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Chronic Pain 1Burkitt Lymphoma 1Advanced Malignant Solid Neoplasm 1

Interventions

Dexamethasone 5Trimethoprim, Sulfamethoxazole Drug Combination 4gamma-Globulins 3Lenalidomide 3Ciprofloxacin 3Bortezomib 3pomalidomide 2fludarabine phosphate 2fludarabine 2elotuzumab 2carfilzomib 2Radiotherapy 2Immunoglobulins, Intravenous 2Cyclophosphamide 2Amoxicillin-Potassium Clavulanate Combination 2siltuximab 1selinexor 1nirogacestat 1iberdomide 1daratumumab 1belantamab mafodotin 1Positron-Emission Tomography 1Melphalan 1Interviews as Topic 1Immunoglobulins 1Focus Groups 1Fecal Microbiota Transplantation 1Clonal Hematopoiesis 1Clavulanic Acid 1Chromatin Immunoprecipitation Sequencing 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Neoplasms, Plasma Cell × siltuximab × Clear all
NCT07106671 2025-08-06

A Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple Myeloma

Institute of Hematology & Blood Diseases Hospital, China

Phase 2 Recruiting
20 enrolled
Plasma cell

Cytokine Release Syndrome, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡